Exponent Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Rhea-AI Summary

Exponent, Inc. (Nasdaq: EXPO) reported strong financial results for Q4 and FY 2022, highlighting a revenue increase of 7% before reimbursements and 10.1% for the full year. Q4 revenues reached $127.4 million, a 12.2% rise, with net income up to $22.5 million ($0.44 per diluted share). For FY 2022, net income was $102.3 million ($1.96 per diluted share). The engineering segment contributed 83% of revenues, reflecting robust demand across various sectors. Looking ahead, Exponent anticipates revenue growth in the high-single to low-double digits for Q1 2023 and FY 2023, reinforcing its strong market position.

Positive

• Q4 revenues increased 12.2% to $127.4 million.
• Net income rose to $22.5 million ($0.44 per diluted share) in Q4 2022.
• FY 2022 revenues up 10.1% to $513.3 million.
• Net income increased to $102.3 million ($1.96 per diluted share) for FY 2022.
• Successful recruitment efforts leading to increased headcount in key business areas.
• Strong demand for services across multiple sectors.

Negative

• Environmental and health segment revenues decreased 2% in Q4 2022.
• Flat revenue growth in the environmental and health segment for FY 2022.

MENLO PARK, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today reported financial results for the fourth quarter and fiscal year 2022 ended December 30, 2022.

“Exponent concluded 2022 with solid results, reflecting broad-based strength across our diversified portfolio of services. In a year marked with evolving macroeconomic challenges and uncertainty, we grew revenues before reimbursements 7% over the prior year and expanded earnings per diluted share, highlighting the strength and resiliency of our business model,” commented Dr. Catherine Corrigan, President and Chief Executive Officer. “Our multidisciplinary team of top-tier scientists and engineers continues to provide critical data, analyses and insights for our clients as society raises expectations for safety, health and the environment.”

“Demand for our proactive services remained strong across the consumer products, electronics, automotive and life sciences sectors. Our reactive engagements were driven by robust litigation-related activity and a diversified portfolio of product safety- and recall-related work spanning multiple industries. We are energized by the opportunities ahead of us in 2023 as we continue to expand our client relationships and enhance our reputation and capabilities across the firm. As innovation and technology become increasingly complex, the critical nature of our insights uniquely positions Exponent to address our clients’ needs throughout the product lifecycle. Exponent has the ability to not only find solutions for today, but to guide clients through the longer-term transformation of their industries for tomorrow,” continued Dr. Corrigan.

Fourth Quarter Financial Results

Total revenues and revenues before reimbursements for the fourth quarter of 2022 increased 12.2% to $127.4 million and 7.9% to $112.6 million as compared to $113.5 million and $104.3 million in the fourth quarter of 2021, respectively. Excluding the impact of foreign exchange, revenues before reimbursements for the Company increased 8.6% in the fourth quarter of 2022 as compared to the prior year period.

Net income increased to $22.5 million, or $0.44 per diluted share, in the fourth quarter of 2022, as compared to $20.4 million, or $0.38 per diluted share, in the same period of 2021.

EBITDA¹ increased to $31.1 million, or 27.6% of revenues before reimbursements, in the fourth quarter of 2022, as compared to $30.2 million, or 28.9% of revenues before reimbursements in the fourth quarter of 2021.

Fiscal Year 2022 Financial Results

Total revenues and revenues before reimbursements for fiscal year 2022 increased 10.1% to $513.3 million and 6.7% to $463.8 million, respectively, as compared to $466.3 million and $434.9 million in fiscal year 2021. Excluding the impact of foreign exchange, revenues before reimbursements for the Company increased 7.2% for the fiscal year 2022 as compared to the prior year period.

Net income increased to $102.3 million, or $1.96 per diluted share, during fiscal year 2022, as compared to $101.2 million, or $1.90 per diluted share, in fiscal year 2021. The tax benefit for the classification of tax adjustments associated with share-based awards realized during fiscal year 2022 was $5.8 million or $0.11 per diluted share, as compared to $10.0 million or $0.19 per diluted share during fiscal year 2021. Inclusive of the tax benefit, Exponent’s consolidated tax rate was 22.6% in fiscal year 2022, as compared to 19.6% in fiscal year 2021.

EBITDA¹ increased to $137.2 million, or 29.6% of revenues before reimbursements, in fiscal year 2022, as compared to $132.3 million, or 30.4% of revenues before reimbursements, in fiscal year 2021.

During fiscal year 2022, Exponent paid $49.2 million in dividends, repurchased $155.9 million of common stock, and closed the period with $161.5 million in cash and cash equivalents. 

In a separate press release today, Exponent announced an increase in its quarterly cash dividend from $0.24 to $0.26 to be distributed on March 24, 2023 and reiterated its intent to continue to pay quarterly dividends.

Business Overview

Exponent’s engineering and other scientific segment represented 83% of the Company’s revenues before reimbursements in both the fourth quarter of 2022 and the fiscal year 2022. Revenues before reimbursements in this segment increased 10% in the fourth quarter and increased 8% during fiscal year 2022 as compared to the prior year period. Growth during the quarter and full year was broad-based with continued strong demand for Exponent's services across the consumer products, electronics, life sciences and automotive sectors.

Exponent’s environmental and health segment represented 17% of the Company’s revenues before reimbursements in both the fourth quarter and fiscal year 2022. Revenues before reimbursements in this segment decreased 2% for the fourth quarter and were flat during the full year 2022, compared to the same period in the prior year. Excluding the impact of foreign exchange, net revenue for the environmental and health segment increased 2% in the fourth quarter of 2022 and 4% during fiscal year 2022 as compared to the prior year period. Growth in this segment was primarily driven by Exponent’s safety-related work evaluating the impacts of chemicals on human health and the environment.

Business Outlook

“We are seeing our accelerated recruitment efforts materialize as we continue to attract a strong pipeline of high-quality talent. Although the demand environment for top-tier talent remains highly competitive, we successfully increased headcount in key areas of the business where we have identified the greatest need and opportunity. We remain laser focused on building our world-class engineering and scientific team to position Exponent at the forefront of innovation and meet the ever-changing needs of our clients and the market,” commented Richard Schlenker, Executive Vice President and Chief Financial Officer.

For the first quarter of 2023 as compared to the same period one year prior, Exponent anticipates:

• Revenues before reimbursements to grow in the high-single to low-double digits; and,
• EBITDA¹ to be 27.5% to 28.2% of revenues before reimbursements.

For the full year 2023 as compared to the same period one year prior, Exponent anticipates:

• Revenues before reimbursements to grow in the high-single to low-double digits; and,
• EBITDA¹ to be 28.0% to 28.5% of revenues before reimbursements.

“For decades, Exponent has stood firmly at the forefront of engineering and scientific excellence, unraveling complexity and illuminating the path forward for clients. Our exceptional talent and multidisciplinary approach position us as a vital partner in helping address our clients’ toughest challenges. We remain optimistic about the strength of Exponent's unique market position, adaptable business model, and strong client relationships. As we look to the year ahead, we remain keenly focused on positioning the company for continued success and creating long-term value for our shareholders,” concluded Dr. Corrigan.

Today's Conference Call Information

Exponent will discuss its financial results in more detail on a conference call today, Thursday, February 2, 2023, starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. The audio of the conference call is available by dialing (844) 481-2781 or (412) 317-0672. A live webcast of the call will be available on the Investor Relations section of the Company's website at www.exponent.com/investors. For those unable to listen to the live webcast, a replay of the call will also be available on the Exponent website, or by dialing (877) 344-7529 or (412) 317-0088 and entering passcode 5182551.

Footnotes

¹ EBITDA is a non-GAAP financial measure defined by the Company as net income before income taxes, interest income, depreciation and amortization. EBITDAS is a non-GAAP financial measure defined by the Company as EBITDA before stock-based compensation. The Company regards EBITDA and EBITDAS as useful measures of operating performance and cash flow to complement operating income, net income and other GAAP financial performance measures. Additionally, management believes that EBITDA and EBITDAS provide meaningful comparisons of past, present and future operating results. Generally, a non-GAAP financial measure is a numerical measure of a company's performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. These measures, however, should be considered in addition to, and not as a substitute or superior to, operating income, cash flows, or other measures of financial performance prepared in accordance with GAAP. A reconciliation of the measures to GAAP is set forth below.

About Exponent

Exponent is an engineering and scientific consulting firm providing solutions to complex problems. Exponent's interdisciplinary organization of scientists, physicians, engineers, and business consultants draws from more than 90 technical disciplines to solve the most pressing and complicated challenges facing stakeholders today. The firm leverages over 50 years of experience in analyzing accidents and failures to advise clients as they innovate their technologically complex products and processes, ensure the safety and health of their users, and address the challenges of sustainability.

Exponent may be reached at (888) 656­-EXPO, info@exponent.com, or www.exponent.com.

Forward Looking Statements

This news release contains, and incorporates by reference, certain “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995, and the rules promulgated pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended) that are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. When used in this document and in the documents incorporated herein by reference, the words “intend,” “anticipate,” “believe,” “estimate,” “expect” and similar expressions, as they relate to the Company or its management, identify such forward-looking statements. Such statements reflect the current views of the Company or its management with respect to future events and are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company’s actual results, performance, or achievements could differ materially from those expressed in, or implied by, any such forward-looking statements. Factors that could cause or contribute to such material differences include the COVID-19 pandemic (including factors relating to measures implemented by governmental authorities or by us to promote the safety of our employees, vendors and clients; other direct and indirect impacts on our business and the businesses of our clients, vendors and other partners; impacts which may, among other things, adversely affect our clients’ ability to utilize our services at the levels they have previously; disruptions of access to our facilities or those of our clients or third parties; and increased and potentially significant economic uncertainty and volatility, including credit and collectability risks and potential disruptions of capital and credit markets), the possibility that the demand for our services may decline as a result of changes in generally applicable and industry-specific economic conditions, the timing of engagements for our services, the effects of competitive services and pricing, the absence of backlog related to our business, our ability to attract and retain key employees, the effect of tort reform and government regulation on our business, and liabilities resulting from claims made against us. Additional risks and uncertainties are discussed in our Annual Report on Form 10-K under the heading “Risk Factors” and elsewhere in the report. The inclusion of such forward-looking information should not be regarded as a representation by the Company or any other person that the future events, plans, or expectations contemplated by the Company will be achieved. The Company undertakes no obligation to release publicly any updates or revisions to any such forward-looking statements.

Source: Exponent, Inc.

EXPONENT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
For the Quarters Ended December 30, 2022 and December 31, 2021
(unaudited)
(in thousands, except per share data)
							Quarters Ended						Years Ended
							December 30,			December 31,			December 30,				December 31,
								2022			2021			2022				2021
Revenues
	Revenues before reimbursements						$	112,589		$	104,336		$	463,820			$	434,850
	Reimbursements							14,766			9,170			49,473				31,419
		Revenues						127,355			113,506			513,293				466,269
Operating expenses
	Compensation and related expenses							74,253			67,556			264,235				278,047
	Other operating expenses							9,341			8,746			35,083				32,594
	Reimbursable expenses							14,766			9,170			49,473				31,419
	General and administrative expenses							6,960			4,656			23,660				15,282
		Total operating expenses						105,320			90,128			372,451				357,342
		Operating income						22,035			23,378			140,842				108,927
Other income (expense), net
	Interest income, net							1,262			12			2,096				66
	Miscellaneous income, net							7,222			5,265			(10,704	)			16,844
		Total other income (expense), net						8,484			5,277			(8,608	)			16,910
		Income before income taxes						30,519			28,655			132,234				125,837
Income taxes								7,995			8,275			29,904				24,635
		Net income					$	22,524		$	20,380		$	102,330			$	101,202
Net income per share:
	Basic						$	0.44		$	0.39		$	1.98			$	1.92
	Diluted						$	0.44		$	0.38		$	1.96			$	1.90
Shares used in per share computations:
	Basic							51,105			52,647			51,727				52,610
	Diluted							51,649			53,359			52,280				53,331

EXPONENT, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
December 30, 2022 and December 31, 2021
(unaudited)
(in thousands)
							December 30,				December 31,
								2022				2021
Assets
Current assets:
	Cash and cash equivalents						$	161,458			$	297,687
	Accounts receivable, net							170,114				139,861
	Prepaid expenses and other assets							17,585				15,214
		Total current assets						349,157				452,762
Property, equipment and leasehold improvements, net								65,539				59,971
Operating lease right-of-use asset								18,007				14,370
Goodwill								8,607				8,607
Other assets								145,352				148,029
		Total Assets					$	586,662			$	683,739
Liabilities and Stockholders' Equity
Current liabilities:
	Accounts payable and accrued liabilities						$	29,115			$	24,504
	Accrued payroll and employee benefits							105,822				103,552
	Deferred revenues							18,834				19,762
	Operating lease liability							5,258				5,164
		Total current liabilities						159,029				152,982
Other liabilities								93,538				103,885
Operating lease liability								13,343				9,807
		Total liabilities						265,910				266,674
Stockholders' equity:
	Common stock							66				66
	Additional paid-in capital							301,002				281,419
	Accumulated other comprehensive loss							(3,587	)			(1,983	)
	Retained earnings							528,810				478,370
	Treasury stock, at cost							(505,539	)			(340,807	)
		Total stockholders' equity						320,752				417,065
							$	586,662			$	683,739

EXPONENT, INC.
EBITDA and EBITDAS (1)
For the Quarters Ended December 30, 2022 and December 31, 2021
(unaudited)
(in thousands)
							Quarter Ended								Years Ended
							December 30,				December 31,				December 30,				December 31,
								2022				2021				2022				2021
Net Income							$	22,524			$	20,380			$	102,330			$	101,202
Add back (subtract):
	Income taxes							7,995				8,275				29,904				24,635
	Interest income, net							(1,262	)			(12	)			(2,096	)			(66	)
	Depreciation and amortization							1,855				1,544				7,079				6,487
		EBITDA (1)						31,112				30,187				137,217				132,258
	Stock-based compensation							4,292				4,024				20,364				19,263
		EBITDAS (1)					$	35,404			$	34,211			$	157,581			$	151,521
(1) EBITDA is a non-GAAP financial measure defined by the Company as net income before income taxes, interest income, depreciation and amortization. EBITDAS is a non-GAAP financial measure defined by the Company as EBITDA before stock-based compensation. The Company regards EBITDA and EBITDAS as useful measures of operating performance and cash flow to complement operating income, net income and other GAAP financial performance measures. Additionally, management believes that EBITDA and EBITDAS provide meaningful comparisons of past, present and future operating results. Generally, a non-GAAP financial measure is a numerical measure of a company's performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. These measures, however, should be considered in addition to, and not as a substitute or superior to, operating income, cash flows, or other measures of financial performance prepared in accordance with GAAP.

FAQ

What were Exponent's Q4 2022 earnings results?

Exponent's Q4 2022 revenues increased 12.2% to $127.4 million with net income rising to $22.5 million or $0.44 per diluted share.

How did Exponent perform in fiscal year 2022?

For FY 2022, Exponent reported total revenues of $513.3 million, up 10.1%, and net income of $102.3 million, or $1.96 per diluted share.

What is Exponent's 2023 revenue outlook?

Exponent anticipates revenue growth in the high-single to low-double digits for both Q1 and full year 2023.

What segments contributed to Exponent's revenue growth?

Exponent's engineering segment, representing 83% of revenues, saw strong demand, while the environmental and health segment faced a 2% decline in Q4.